China SXT Pharmaceuticals, Inc. (SXTC): Price and Financial Metrics
China SXT Pharmaceuticals, Inc. (SXTC)
Today's Latest Price: $0.70 USD
Updated Jan 21 4:00pm
Add SXTC to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SXTC Stock Summary
- With a year-over-year growth in debt of 1,645.91%, China SXT Pharmaceuticals Inc's debt growth rate surpasses 98.69% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, China SXT Pharmaceuticals Inc is reporting a growth rate of -532.36%; that's higher than merely 3.71% of US stocks.
- As for revenue growth, note that SXTC's revenue has grown -74.91% over the past 12 months; that beats the revenue growth of merely 2.18% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to China SXT Pharmaceuticals Inc are BRFS, VRME, TKC, CENX, and LOMA.
- Visit SXTC's SEC page to see the company's official filings. To visit the company's web site, go to www.sxtchina.com.
SXTC Stock Price Chart Interactive Chart >
SXTC Price/Volume Stats
| Current price | $0.70 | 52-week high | $1.48 |
| Prev. close | $0.62 | 52-week low | $0.22 |
| Day low | $0.62 | Volume | 20,871,672 |
| Day high | $0.77 | Avg. volume | 16,315,869 |
| 50-day MA | $0.37 | Dividend yield | N/A |
| 200-day MA | $0.38 | Market Cap | 24.27M |
China SXT Pharmaceuticals, Inc. (SXTC) Company Bio
China Sxt Pharmaceuticals, Inc. engages in the development, manufacture, marketing, sales, research and development of Chinese traditional medicine. It sells Advanced TCMP, Fine TCMP and Regular TCMP products. The company sell its products under "Suxuantang" brand name. The company was founded by Zhou Feng in 2005 and is headquartered in Taizhou, China.
SXTC Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $0.70 | $0.02 | -96% |
Below please find a table outlining a discounted cash flow forecast for SXTC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that China SXT Pharmaceuticals Inc ranked in the 7th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for SXTC, they are:
- Its compound free cash flow growth rate, as measured over the past 1.87 years, is -0.24% -- higher than merely 6.79% of stocks in our DCF forecasting set.
- As a business, SXTC is generating more cash flow than merely 3.98% of positive cash flow stocks in the Healthcare.
- China SXT Pharmaceuticals Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -2.1. This coverage rate is greater than that of only 17.33% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -96% |
| 1% | -96% |
| 2% | -96% |
| 3% | -96% |
| 4% | -96% |
| 5% | -96% |
Want more companies with a valuation profile/forecast similar to that of China SXT Pharmaceuticals Inc? See NVST, TEVA, INFU, LUMO, and OSMT.
Loading social stream, please wait...